New Phase 3 Endometrial Cancer Trial Planned for Selinexor After Talks With FDA
March 3rd 2022Topline findings from the phase 3 SIENDO trial did not appear to likely support a supplemental new drug application use of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer, prompting the creation of a new phase 3 trial to support a future submission.
Phase 2 ENPAC Trial Shows Feasibility of Enzalutamide Triplet in Endometrioid Endometrial Cancer
March 25th 2021The androgen receptor inhibitor enzalutamide, an approved therapy for certain types of prostate cancer, has shown activity for the treatment of patients with recurrent or advanced endometrioid endometrial cancer.
Addition of Olaparib to Cediranib Does Not Induce Superior Efficacy in Advanced Endometrial Cancer
March 22nd 2021The combination of cediranib and olaparib demonstrated modest efficacy in patients with recurrent, metastatic, or persistent endometrial cancer; however, this was not significantly different compared to cediranib alone.
Pembrolizumab/Lenvatinib Combo Shows Survival Benefit in Advanced Endometrial Cancer
March 19th 2021Following a prior announcement that the phase 3 KEYNOTE-775 trial met both primary end points of progression-free and overall survival benefit, data for the pembrolizumab/lenvatinib combination were presented at the Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer.
Study Suggests NACT to be Important Treatment Option for Metastatic Endometrial Cancer
December 27th 2020“These findings suggest that similar to its benefits in ovarian cancer, NACT could potentially lower perioperative morbidity and may serve as an important treatment option among women with metastatic endometrial cancer,” the study authors wrote.
Phase 3 KEYNOTE-775/Study 309 Trial Meets Dual Primary End Points in Advanced Endometrial Cancer
December 16th 2020The pivotal phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of pembrolizumab (Keytruda) plus lenvatinib (Lenvima) met its dual primary end points of overall and progression-free survival in patients with advanced endometrial cancer.
Patients with Endometrial Cancer Pose High Risk of Dying from Cardiovascular Disease
December 2nd 2019Patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the year after diagnosis, suggesting the necessity of early involvement of cardiologists for these patients.
Breaking New Ground in the Treatment of Advanced Endometrial Cancer
June 19th 2019Dr. Makker summarizes the standard of care for the treatment of advanced endometrial cancer, with a look forward to the multitude of clinical trials evaluating novel therapy combinations that are currently enrolling patients or underway.